modelGlucarpidase

Extends from Pharmacolibrary.Drugs.ATC.V.V03AF09.

Information

name:Glucarpidase
ATC code:V03AF09
route:intravenous
compartments:1
dosage:3900mg
volume of distribution:3.5L
clearance:2.4L/h
other parameters in model implementation

Glucarpidase is an enzyme (carboxypeptidase G2) used to rapidly lower toxic plasma levels of methotrexate in patients with delayed methotrexate clearance due to renal impairment. It hydrolyzes methotrexate into inactive metabolites. The drug is approved for use in the United States for this specific indication.

Pharmacokinetics

Pharmacokinetics in adult patients with impaired renal function who received glucarpidase 50 Units/kg intravenously as a single dose.

References

  1. Fukaya, Y, et al., & Kawamoto, H (2023). Development of a population pharmacokinetics and pharmacodynamics model of glucarpidase rescue treatment after high-dose methotrexate therapy. Frontiers in oncology 13 1003633–None. DOI:10.3389/fonc.2023.1003633 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36793598

  2. Taylor, ZL, et al., & Ramsey, LB (2020). MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase. Clinical pharmacology and therapeutics 108(3) 635–643. DOI:10.1002/cpt.1957 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32558929

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)